CLAIMS

1. Use of an inhibitor of secreted Phospholipase A2 group IB (GIBsPLA2) in the manufacture of a medicament for treating an immune disorder in a subject in need thereof.
2. The use of claim 1, wherein the medicament induces or stimulates an immune response.
3. The use of claim 1 or 2, wherein the GIBsPLA2 inhibitor is selected from an anti-GIBsPLA2 antibody or a derivative thereof, an inhibitory nucleic acid, a soluble receptor, a peptide, or a small drug.
4. The use of claim 3, wherein the GIBsPLA2 inhibitor or ligand is selected from anti-GIBsPLA2 polyclonal antibodies, monoclonal antibodies, fragments thereof selected from F(ab')2 and Fab fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (VHHs or Nanobodies), bivalent antibody fragments (diabodies), as well as recombinantly and synthetically produced binding partners, human antibodies or humanized antibodies or fragments thereof.
5. The use of anyone of claims 1 to 4, wherein the medicament induces or stimulates CD4 T cells in the subject.
6. The use of anyone of claims 1 to 5, wherein the subject is immuno-deficient or immuno-depressed
7. The use of anyone of claims 1 to 5, wherein the subject has an infectious disease
8. The use of claim 7, wherein the subject has a viral infection.
9. The use of anyone of the preceding claims, for treating AIDS in a HIV-infected subject.
10. The use of claim 9, to suppress or reverse HIV-mediated immunodeficiency.
11. The use of anyone of claims 1 to 5, wherein the subject has a cancer.
12. The use of a secreted Phospholipase A2 group IB (GIBsPLA2) agonist or activator in the manufacture of a medicament for treating a disease caused by a pathologic or abnormal immune response in a subject in need thereof by decreasing said immune response.
13. The use of claim 12, wherein the GIBsPLA2 agonist or activator is a GIBsPLA2 protein or a fragment thereof.

14. The use of claim 12 or 13, wherein the subject has a disease selected from an autoimmune disorder, an inflammatory disease, a cancer, an urticaria, an eczema, an allergy, or asthma.
15. The use of any one of claims 12-14, for reducing graft rejection or reducing GVHD in a subject.
16. The use of anyone of the preceding claims, wherein the medicament is to be administered by injection, preferably intramuscular, subcutaneous, transdermal, intraveinous or intraarterial; by nasal, oral, mucosal,rectal administration or by inhalation.
17. A pharmaceutical composition comprising a specific inhibitor of GIBsPLA2 and a pharmaceutically acceptable carrier or excipient.
18. Use of an immunogen that induces an anti-GIBsPLA2 immune response, in the manufacture of a medicament for modulating the immune system in a subject having an immune disorder.
19. The use of claim 18, wherein the immunogen comprises a human or animal GIBsPLA2 protein, protein fragment or peptide, or an antigenic fragment or mimotope thereof.
20. The use of claim 18 or 19, wherein the immunogen is in free form, polymerized, or chemically or physically modified, and/or linked to a carrier.
21. The use of any one of claims 18-20, wherein the immunogen is combined with an adjuvant.
22. The use of any one of claims 18-21, wherein the immunogen induces neutralizing antibodies.
23. A vaccine composition comprising an immunogen inducing an anti-GIBsPLA2 immune response, a pharmaceutically acceptable carrier or excipient and, optionally, an adjuvant.
24. The composition of claim 23, wherein the immunogen comprises a GIBsPLA2 protein or peptide, or an antigenic fragment or mimotope thereof.
25. The composition of claim 24, wherein the GIBsPLA2 protein or antigenic fragment or mimotope thereof is in free form, polymerized, or chemically or physically modified, or linked to a carrier and, optionally combined with an adjuvant.
26. A method for diagnosing human immunodeficiency associated with T cell alteration, comprising:

(a) providing a sample containing body fluid or a tissue fragment or cells from a subject, and

(b) detecting or quantifying GIBsPLA2 in the sample.